+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lambert-Eaton Myasthenic Syndrome Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 119 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5724452
Description Jump to:

Industry Outlook

The Lambert-Eaton Myasthenic Syndrome (LEMS) market is keen to represent linear growth at a compounded annual growth rate (CAGR) of 6.7% during the forecast period from 2022 to 2030. LEMS is a rare autoimmune disorder which is manifested by the clinical triad which comprises of reduced tendon reflexes, autonomic symptoms and proximal muscle weakness. Most of the patients suffering with LEMS go undiagnosed at an early age due to its overlapping symptoms similar to small cell lung cancer (SCLC).

Recent FDA approval of amifampridine for treating LEMS in children and fast track & orphan drug designation to incentivize its growth during the forecast period

Currently there is no permanent cure for the treatment of LEMS disease in children, the medicine prescribed by physicians worldwide are to attenuate the clinical manifestations related to LEMS disease. Depending on the identification of the symptoms occurring in the adult population the drugs prescribed for its treatment are potassium channel blockers, cholinesterase inhibitor, immune therapy, intravenous immunoglobulin, Plasmapheresis etc. USFDA has recently approved amifampridine for the treatment of LEMS in children from 6 to 17 years of age. It has received orphan drug and fast track designation status which will proactively incentivize the drug development for curing rare diseases.

Significant rise in clinical research to cure orphan diseases and domicile of major players together drive the market growth in North America region

North America is currently dominating the regional segment for Lambert-Eaton Myasthenic syndrome (LEMS) market holding 39% share. The major factors responsible for its positive growth profile are significant rise in clinical research activities to cure orphan diseases. According to the Center for Disease Control and Prevention (CDC), research findings approximately 3% of the patients suffering with small cell lung cancer (SCLC) are suffering with Lambert-Eaton Myasthenic syndrome (LEMS). The prevalence rate of SCLC in the United States is 5 cases per million population. Domicile of major players such as Biomarin Pharmaceutical, Inc., Catalyst, Pharmaceuticals, Inc., Merck & Co., Inc. etc. propel the market growth in North America region. Europe holds the second position representing a market share of 34.5% owing to the high incidence rate of LEMS in the European community. As per the research citing of European LEMS Registry the incidence rate is 0.48 to 0.75 per million people, the low prevalence rate I comparison to the incidence rate is due to the poor survival of LEMS patient with paraneoplastic type of disease. Asia Pacific is currently holding 14% market share primarily due to large patient population suffering with SCLC and proactive government initiatives in providing financial aid for the treatment of rare diseases.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Lambert-Eaton Myasthenic Syndrome market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Lambert-Eaton Myasthenic Syndrome market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Treatment

  • Potassium Channel Blockers (Amifampridine)
  • Cholinesterase Inhibitor (Pyridostigmine)
  • Immune Therapy
  • Intravenous Immunoglobulin
  • Plasmapheresis

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Lambert-Eaton Myasthenic Syndrome market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Lambert-Eaton Myasthenic Syndrome market?
  • Which is the largest regional market for Lambert-Eaton Myasthenic Syndrome market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Lambert-Eaton Myasthenic Syndrome market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Lambert-Eaton Myasthenic Syndrome market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Lambert-Eaton Myasthenic Syndrome Market
2.2. Global Lambert-Eaton Myasthenic Syndrome Market, By Treatment, 2021 (US$ Million)
2.3. Global Lambert-Eaton Myasthenic Syndrome Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021

3. Lambert-Eaton Myasthenic Syndrome Market: Competitive Analysis
3.1. Market Positioning of Key Lambert-Eaton Myasthenic Syndrome Market Vendors
3.2. Strategies Adopted by Lambert-Eaton Myasthenic Syndrome Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030

4. Lambert-Eaton Myasthenic Syndrome Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Lambert-Eaton Myasthenic Syndrome Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Potassium Channel Blockers (Amifampridine)
5.3.2. Cholinesterase Inhibitor (Pyridostigmine)
5.3.3. Immune Therapy
5.3.4. Intravenous Immunoglobulin
5.3.5. Plasmapheresis

6. North America Lambert-Eaton Myasthenic Syndrome Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
6.3.Lambert-Eaton Myasthenic Syndrome Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)

7. UK and European Union Lambert-Eaton Myasthenic Syndrome Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
7.3.Lambert-Eaton Myasthenic Syndrome Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)

8. Asia Pacific Lambert-Eaton Myasthenic Syndrome Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
8.3.Lambert-Eaton Myasthenic Syndrome Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)

9. Latin America Lambert-Eaton Myasthenic Syndrome Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
9.3.Lambert-Eaton Myasthenic Syndrome Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)

10. Middle East and Africa Lambert-Eaton Myasthenic Syndrome Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
10.3.Lambert-Eaton Myasthenic Syndrome Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)

11. Company Profile
11.1. Allergan, Plc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Biomarin Pharmaceutical, Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Catalyst Pharmaceuticals, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. F. Hoffman-La Roche Ltd.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. GlaxoSmithkline, Plc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Jacobus Pharmaceutical Company, Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Kawasumi Laboratories, Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Merck & Co., Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Mitsubishi Pharma Corporation
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Novartis AG
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives

List of Figures
Figure 1 Global Lambert-Eaton Myasthenic Syndrome Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Lambert-Eaton Myasthenic Syndrome Market: Quality Assurance
Figure 5 Global Lambert-Eaton Myasthenic Syndrome Market, By Treatment, 2021
Figure 6 Global Lambert-Eaton Myasthenic Syndrome Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Lambert-Eaton Myasthenic Syndrome Market, 2021
Figure 8 Market Positioning of Key Lambert-Eaton Myasthenic Syndrome Market Players, 2021
Figure 9 Global Lambert-Eaton Myasthenic Syndrome Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Lambert-Eaton Myasthenic Syndrome Market, By Treatment, 2021 Vs 2030, %
Figure 11 U.S. Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 12 Canada Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 14 UK Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 15 Germany Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 16 Spain Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 17 Italy Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 18 France Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 20 China Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 21 Japan Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 22 India Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 23 Australia Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 24 South Korea Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 26 Brazil Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 27 Mexico Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 29 GCC Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 30 Africa Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030

List of Tables
Table 1 Global Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 2 North America Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 3 U.S. Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 4 Canada Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 5 Rest of North America Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 6 UK and European Union Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 7 UK Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 8 Germany Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 9 Spain Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 10 Italy Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 11 France Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 12 Rest of Europe Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 13 Asia Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 14 China Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 15 Japan Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 16 India Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 17 Australia Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 18 South Korea Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 19 Latin America Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 20 Brazil Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 21 Mexico Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 22 Rest of Latin America Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 23 Middle East and Africa Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 24 GCC Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 25 Africa Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)

Companies Mentioned

  • Biomarin Pharmaceutical Inc.
  • Catalyst
  • Pharmaceuticals Inc.
  • Merck & Co. Inc.

Related Topics

Related Reports

Lambert-Eaton Myasthenic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Lambert-Eaton Myasthenic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 137 Pages
  • Global
From
Lambert-Eaton Myasthenic Syndrome (LEMS) - Pipeline Insight, 2024 - Product Image

Lambert-Eaton Myasthenic Syndrome (LEMS) - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 145 Pages
  • Global
From
Blau Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Blau Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 133 Pages
  • Global
From
Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029 - Product Image

Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029

  • Report
  • 1200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.